Fig. 7From: A nomogram based on 9-lncRNAs signature for improving prognostic prediction of clear cell renal cell carcinomaEstimated half-maximal inhibitory concentration (IC50) of high risk group and low risk group for antitumor durgs: axitinib, cisplatin, gemcitabine, pazopanib, sorafenib and temsirolimusBack to article page